Studies how normal skin cells change into moles and then melanoma
Studies molecular changes from moles to melanoma in young people with large moles.
Plain-language title generated from the registry record
Registry title: Understanding the Transition from Normal Melanocytes to Nevus to Melanoma
Key facts
- Where
- Barcelona, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a large congenital nevus (a birthmark-type mole present from birth). It studies how such moles can change into melanoma.
- Age
- Over 18 years
- Sex
- All sexes can join.
- Disease stage
- Congenital nevus with an estimated size of 20 cm (7.9 in).
Main reasons for not taking part
- No biological material available
- Informed consent not signed
Read by machine on 12 November 2026.
Where in Spain
- Hospital Clínic de Barcelona (Dermatology service)Barcelona, SpainContact: Susana Puig Sardà, PhD, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fundacion Clinic per a la Recerca Biomédica
- Trial code
- NCT06605417
- Record updated
- 27 February 2025
- Original description
The primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in CAYA patients with L/GCMN. The secondary objectives are:Read full original descriptionShow less
Understanding the Transition from Normal Melanocytes to Nevus to Melanoma (NevustoMel)
The primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in CAYA patients with L/GCMN. The secondary objectives are:
* To longitudinally characterize the cell-free DNA (cfDNA) from CAYA patients. * To improve the early diagnosis and treatments for intermediate conditions such as L/GCMN through evidence-based interpretation of personal risk from endogenous or exogenous sources. * To test pre-clinical strategies to best model and improve patient response.
Inclusion: Congenital nevus with estimated size of 20 cm; Be over 18 years of age.
Exclusion: No available biological material; Not having signed the informed consent.